Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Read here: https://meetinglibrary.asco.org/record/186864/abstract
Advertisement